The Law Firm of Weiss & Lurie Investigates Anadys Pharmaceuticals, Inc.
22 October 2011 - 1:53AM
Business Wire
Weiss & Lurie, a national class action and shareholder
rights law firm with offices in New York City and Los Angeles, is
investigating possible breaches of fiduciary duty and other
violations of law by the Board of Directors of Anadys
Pharmaceuticals, Inc. (NASDAQ: ANDS) arising from its proposed
acquisition by Roche Holding for $3.70 per share in cash.
Under the agreement, Roche will commence an all cash tender
offer for all outstanding Anadys shares. The tender offer is
expected to close within the fourth quarter of 2011, subject to
customary conditions, including the tender of a majority of the
outstanding Anadys shares.
Weiss & Lurie is investigating whether Anadys’ Board acted
in the best interests of its shareholders in approving the
transaction. At least one analyst has set a price target of Anadys
at $4.00 per share.
If you own Anadys shares and would like more information about
your rights as a shareholder or additional information concerning
our investigation, please contact Michael A. Rogovin either by
email at info@weisslurie.com or by telephone at (888) 593-4771.
Weiss & Lurie has litigated hundreds of stockholder class
and derivative actions for violations of corporate and fiduciary
duties. We have recovered over a billion dollars for defrauded
institutions and individuals and obtained important corporate
governance in these cases. If you have information or would like
legal advice concerning possible corporate wrongdoing (including
insider trading, waste of corporate assets, accounting fraud, or
issuing materially misleading information), consumer fraud
(including false advertising, defective products, or other
deceptive business practices), or anti-trust violations, please
email us at info@weisslurie.com or fill out the form on our
website, http://www.weisslurie.com/contact/report_fraud/. Attorney
Advertising. Past results do not guarantee a similar outcome.
Anadys (NASDAQ:ANDS)
Historical Stock Chart
From May 2024 to Jun 2024
Anadys (NASDAQ:ANDS)
Historical Stock Chart
From Jun 2023 to Jun 2024
Real-Time news about Anadys Pharmaceuticals (MM) (NASDAQ): 0 recent articles
More Weiss & Lurie News Articles